1 |
Nox inhibitors : A potential future medicine for ischemia strokeJackson, Charlotte January 2018 (has links)
This study investigated the neuroprotective effects of novel small molecule NOX inhibitors after induction of an ischemic stroke model on Neuroblastoma cells (NB69). Previous findings show that high levels of reactive oxygen species (ROS) have been identified for playing a role in causing inflammation, cellular damage and apoptosis in many cardiovascular diseases. It is believed that by inhibiting the Nox enzymes that generate ROS, the damage caused to the brain (measured as % cell viability) would be decreased. NOX2 and NOX4 gene expression what validated in NB69 cells using PCR, gel electrophoresis and GAPDH as a reference gene. Stroke was modelled by using the oxygen-glucose depletion model and reperfusion injury was modelling by replenishing glucose and oxygen supplies to the cell and incubator for 24-72hrs. Gene expression of NOX4 expression after 1hr ischemia and 24-48hrs reperfusion showed there was an increase in relative expression after 24hrs and a decrease in expression after 48hrs. No gene expression analysis could be shown for NOX2. Cell viability was measured amongst treatment groups using the MTS assay. Statistical analysis consisted of Shapiro Wilk tests, One-way ANOVAs, Tukey tests and ROUT Outlier analysis. Only M114 was seen to have a statistically significant neuroprotective effect on the cells ( after 1hr ischemia, 24+48hrs reperfusion and 2hr ischemia + 48hr reperfusion). After 72hrs reperfusion all three treatments reduced cell viability significantly from the negative control group (p<0.0001) highlighting the importance of ROS signalling in neural cells and the consequences of eradicating it. Media was changed on plates after 48hrs reperfusion. These findings show that all three substances have some effect on the cells and can target their NOX enzymes and identifies M114 as a potential new treatment for stroke patients.
|
2 |
Delayed Stroke after Aneurysm Treatment with Flow Diverters in Small Cerebral Vessels: A Potentially Critical Complication Caused by Subacute VasospasmSchob, Stefan, Richter, Cindy, Scherlach, Cordula, Lindner, Dirk, Planitzer, Uwe, Hamerla, Gordian, Ziganshyna, Svitlana, Werdehausen, Robert, Struck, Manuel Florian, Schob, Bernd, Gaber, Khaled, Meixensberger, Jürgen, Hoffmann, Karl-Titus, Quäschling, Ulf 06 April 2023 (has links)
Flow diversion (FD) is a novel endovascular technique based on the profound alteration
of cerebrovascular hemodynamics, which emerged as a promising minimally invasive therapy for
intracranial aneurysms. However, delayed post-procedural stroke remains an unexplained concern.
A consistent follow-up-regimen has not yet been defined, but is required urgently to clarify the
underlying cause of delayed ischemia. In the last two years, 223 patients were treated with six
different FD devices in our center. We identified subacute, FD-induced segmental vasospasm (SV) in
36 patients as a yet unknown, delayed-type reaction potentially compromising brain perfusion to a
critical level. Furthermore, 86% of all patients revealed significant SV approximately four weeks after
treatment. In addition, 56% had SV with 25% stenosis, and 80% had additional neointimal hyperplasia.
Only 13% exhibited SV-related high-grade stenosis. One of those suffered stroke due to prolonged
SV, requiring neurocritical care and repeated intra-arterial (i.a.) biochemical angioplasty for seven
days to prevent territorial infarction. Five patients suffered newly manifested, transient hemicrania
accompanying a compensatorily increased ipsilateral leptomeningeal perfusion. One treated vessel
obliterated permanently. Hence, FD-induced SV is a frequent vascular reaction after FD treatment,
potentially causing symptomatic ischemia or even stroke, approximately one month post procedure.
A specifically early follow-up-strategy must be applied to identify patients at risk for ischemia,
requiring intensified monitoring and potentially anti-vasospastic treatment.
|
3 |
Untersuchungen zur endogenen Neurogenese an Ephrin-B3-defizienten Mäusen nach zerebraler Ischämie / Ephrin B3 deficiency increases post-ischemic endogenous neurogenesis in mice but fails to improve functional recoveryBretschneider, Eva 17 January 2012 (has links)
No description available.
|
4 |
Alternative targets for the treatment of stroke /Ajmo, Craig T. January 2007 (has links)
Dissertation (Ph.D.)--University of South Florida, 2007. / Includes vita. Includes bibliographical references. Also available online.
|
Page generated in 0.0467 seconds